Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Trial Profile

An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone cancer; Giant cell tumours
  • Focus Adverse reactions; Registrational
  • Sponsors Amgen

Most Recent Events

  • 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.(17 May 2018)
  • 30 Jun 2020 According to a BeiGene media release, the Amgen gained approval from the China National Medical Products Administration (NMPA) for XGEVA in May 2019 for the treatment of adults and skeletally mature adolescents (defined by at least one mature long bone and with a body weight = 45 kg) with GCTB that is unresectable or where surgical resection is likely to result in severe morbidity, based on the data from this and NCT00680992.
  • 05 Nov 2019 Results published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top